EGFR-TKIs have achieved tumor regression in many EGFR-mutated NSCLC cases; however, all tumors eventually become resistant to EGFR-TKIs through various mechanisms, including secondary EGFR mutations and MET gene amplification [4,5,6]. The gene discussed is EGFR; the disease is neoplasm.